Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2016, Article ID 3140372, 5 pages
http://dx.doi.org/10.1155/2016/3140372
Review Article

From Inflammation to Prostate Cancer: The Role of Inflammasomes

Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC 29208, USA

Received 23 March 2016; Revised 17 May 2016; Accepted 9 June 2016

Academic Editor: Mohammad H. Ather

Copyright © 2016 Dev Karan and Seema Dubey. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA—A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Karan, J. B. Thrasher, and D. Lubaroff, “Prostate cancer: genes, environment, immunity and the use of immunotherapy,” Prostate Cancer and Prostatic Diseases, vol. 11, no. 3, pp. 230–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Martinon and J. Tschopp, “Inflammatory caspases and inflammasomes: master switches of inflammation,” Cell Death and Differentiation, vol. 14, no. 1, pp. 10–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. B. K. Davis, H. Wen, and J. P.-Y. Ting, “The Inflammasome NLRs in immunity, inflammation, and associated diseases,” Annual Review of Immunology, vol. 29, pp. 707–735, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Cohen, B. A. Shannon, M. Phillips, R. E. Moorin, T. M. Wheeler, and K. L. Garrett, “Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features,” The Journal of Urology, vol. 179, no. 5, pp. 1762–1767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. M. De Marzo, E. A. Platz, S. Sutcliffe et al., “Inflammation in prostate carcinogenesis,” Nature Reviews Cancer, vol. 7, no. 4, pp. 256–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Sciarra, G. Mariotti, S. Salciccia et al., “Prostate growth and inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 108, no. 3–5, pp. 254–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Vasto, G. Carruba, G. Candore, E. Italiano, D. Di Bona, and C. Caruso, “Inflammation and prostate cancer,” Future Oncology, vol. 4, no. 5, pp. 637–645, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. W. G. Nelson, A. M. De Marzo, T. L. DeWeese et al., “The role of inflammation in the pathogenesis of prostate cancer,” Journal of Urology, vol. 172, no. 5, pp. S6–S12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Kuper, H.-O. Adami, and D. Trichopoulos, “Infections as a major preventable cause of human cancer,” Journal of Internal Medicine, vol. 248, no. 3, pp. 171–183, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. D. G. DeNardo, M. Johansson, and L. M. Coussens, “Immune cells as mediators of solid tumor metastasis,” Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 11–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. Swann, M. D. Vesely, A. Silva et al., “Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 2, pp. 652–656, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. M. Moreira, D. G. Bostwick, G. L. Andriole et al., “Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy,” The Journal of Urology, vol. 194, no. 5, pp. 1241–1246, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Moreira, J. C. Nickel, G. L. Andriole, R. Castro-Santamaria, and S. J. Freedland, “Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: results from the REDUCE study,” The Prostate, vol. 75, no. 13, pp. 1492–1498, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. T. H. Yli-Hemminki, M. Laurila, A. Auvinen et al., “Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial,” BJU International, vol. 112, no. 6, pp. 735–741, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. B. H. Yun, E. C. Hwang, H. S. Yu et al., “Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?” International Urology and Nephrology, vol. 47, no. 8, pp. 1251–1257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Zhang, I. A. Sesterhenn, R. R. Connelly, F. K. Mostofi, and J. W. Moul, “Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen,” The Journal of Urology, vol. 163, no. 1, pp. 131–136, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. B. A. Rybicki, O. N. Kryvenko, Y. Wang et al., “Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 19, pp. 145–150, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Gurel, M. S. Lucia, I. M. Thompson Jr. et al., “Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial,” Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 5, pp. 847–856, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Strasner and M. Karin, “Immune infiltration and prostate cancer,” Frontiers in Oncology, vol. 5, article 128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Vral, V. Magri, E. Montanari et al., “Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients,” International Journal of Oncology, vol. 41, no. 6, pp. 1950–1958, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Celma, P. Servián, J. Planas et al., “Clinical significance of proliferative inflammatory atrophy in prostate biopsy,” Actas Urologicas Espanolas, vol. 38, no. 2, pp. 122–126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Fujita, M. Hosomi, G. Tanigawa, M. Okumi, H. Fushimi, and S. Yamaguchi, “Prostatic inflammation detected in initial biopsy specimens and urinary Pyuria are predictors of negative repeat prostate biopsy,” The Journal of Urology, vol. 185, no. 5, pp. 1722–1727, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. D. P. Nguyen, J. Li, S. S. Yadav, and A. K. Tewari, “Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer,” BJU International, vol. 114, no. 2, pp. 168–176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Hoesel and J. A. Schmid, “The complexity of NF-κB signaling in inflammation and cancer,” Molecular Cancer, vol. 12, no. 1, article 86, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Salazar, M. Castellan, S. S. Shirodkar, and B. L. Lokeshwar, “Chemokines and chemokine receptors as promoters of prostate cancer growth and progression,” Critical Reviews in Eukaryotic Gene Expression, vol. 23, no. 1, pp. 77–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. D. J. J. Waugh, C. Wilson, A. Seaton, and P. J. Maxwell, “Multi-faceted roles for CXC-chemokines in prostate cancer progression,” Frontiers in Bioscience, vol. 13, no. 12, pp. 4595–4604, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Heidegger, J. Höfer, M. Luger et al., “Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?” The Prostate, vol. 75, no. 16, pp. 1904–1909, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. E. B. Holliday, N. F. Dieckmann, T. L. McDonald, A. Y. Hung, C. R. Thomas Jr., and L. J. Wood, “Relationship between fatigue, sleep quality and inflammatory cytokines during external beam radiation therapy for prostate cancer: a prospective study,” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, vol. 118, no. 1, pp. 105–111, 2016. View at Google Scholar
  32. S. Dwivedi, A. Goel, S. M. Natu, A. Mandhani, S. Khattri, and K. K. Pant, “Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: A Prospective Study,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 7, pp. 1843–1848, 2011. View at Google Scholar · View at Scopus
  33. K. Fujita, C. M. Ewing, W. B. Isaacs, and C. P. Pavlovich, “Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status,” International Journal of Cancer, vol. 129, no. 2, pp. 424–432, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. R. Bauskin, D. A. Brown, T. Kuffner et al., “Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer,” Cancer Research, vol. 66, no. 10, pp. 4983–4986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. K. S. Selander, D. A. Brown, G. B. Sequeiros et al., “Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases,” Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 3, pp. 532–537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Tu, G. Bhagat, G. Cui et al., “Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice,” Cancer Cell, vol. 14, no. 5, pp. 408–419, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Terme, E. Ullrich, L. Aymeric et al., “IL-18 induces PD-1-dependent immunosuppression in cancer,” Cancer Research, vol. 71, no. 16, pp. 5393–5399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Schroder and J. Tschopp, “The Inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Y. Chen and G. Núñez, “Inflammasomes in intestinal inflammation and cancer,” Gastroenterology, vol. 141, no. 6, pp. 1986–1999, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Fabbi, G. Carbotti, and S. Ferrini, “Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP,” Journal of Leukocyte Biology, vol. 97, no. 4, pp. 665–675, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. D. A. C. Deans, S. J. Wigmore, H. Gilmour, S. Paterson-Brown, J. A. Ross, and K. C. H. Fearon, “Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer,” British Journal of Cancer, vol. 95, no. 11, pp. 1568–1575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. C. A. Dinarello, “Immunological and inflammatory functions of the interleukin-1 family,” Annual Review of Immunology, vol. 27, pp. 519–550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Okamoto, W. Liu, Y. Luo et al., “Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1β,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6477–6488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Dostert, G. Guarda, J. F. Romero et al., “Malarial hemozoin is a Nalp3 inflammasome activating danger signal,” PLoS ONE, vol. 4, no. 8, Article ID e6510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Hornung, F. Bauernfeind, A. Halle et al., “Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization,” Nature Immunology, vol. 9, no. 8, pp. 847–856, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. C.-S. Chen, P.-J. Chang, W.-Y. Lin, Y.-C. Huang, and D.-R. Ho, “Evidences of the inflammasome pathway in chronic prostatitis and chronic pelvic pain syndrome in an animal model,” The Prostate, vol. 73, no. 4, pp. 391–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Kashyap, S. Pore, Z. Wang, J. Gingrich, N. Yoshimura, and P. Tyagi, “Inflammasomes are important mediators of prostatic inflammation associated with BPH,” Journal of Inflammation, vol. 12, article 37, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Ponomareva, H. Liu, X. Duan et al., “AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer,” Molecular Cancer Research, vol. 11, no. 10, pp. 1193–1202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. Q. Liu, M. R. Russell, K. Shahriari et al., “Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features,” Cancer Research, vol. 73, no. 11, pp. 3297–3305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Schulze, K. Weber, A. Baranowsky et al., “P65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts,” Cancer Letters, vol. 317, no. 1, pp. 106–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. C. A. Dinarello, A. Simon, and J. W. M. Van Der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 633–652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. D. S. Hong, D. Hui, E. Bruera et al., “MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: An open-label, phase 1 dose-escalation and expansion study,” The Lancet Oncology, vol. 15, no. 6, pp. 656–666, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. “A phase 3 study to evaluate Xilonix as an anticancer therapy in patients with symptomatic colorectal cancer,” https://clinicaltrials.gov/ct2/show/NCT02138422.
  54. M. T. Chow, J. Sceneay, C. Paget et al., “NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases,” Cancer Research, vol. 72, no. 22, pp. 5721–5732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Knauf, J. R. Asplin, I. Granja et al., “NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy,” Kidney International, vol. 84, no. 5, pp. 895–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. I. C. Allen, E. M. Tekippe, R.-M. T. Woodford et al., “The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer,” The Journal of Experimental Medicine, vol. 207, no. 5, pp. 1045–1056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Kolb, G.-H. Liu, A. M. Janowski, F. S. Sutterwala, and W. Zhang, “Inflammasomes in cancer: a double-edged sword,” Protein and Cell, vol. 5, no. 1, pp. 12–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Terlizzi, V. Casolaro, A. Pinto, and R. Sorrentino, “Inflammasome: cancer's friend or foe?” Pharmacology and Therapeutics, vol. 143, no. 1, pp. 24–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. S. K. Drexler and A. S. Yazdi, “Complex roles of inflammasomes in carcinogenesis,” Cancer Journal, vol. 19, no. 6, pp. 468–472, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Guo, J. B. Callaway, and J. P.-Y. Ting, “Inflammasomes: mechanism of action, role in disease, and therapeutics,” Nature Medicine, vol. 21, no. 7, pp. 677–687, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Zitvogel, O. Kepp, L. Galluzzi, and G. Kroemer, “Inflammasomes in carcinogenesis and anticancer immune responses,” Nature Immunology, vol. 13, no. 4, pp. 343–351, 2012. View at Publisher · View at Google Scholar · View at Scopus